We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Contents
- Rationale
- Rationale: low target efficacy
- Side effects from chemotherapy
- Rationale: nanoparticles
- Part 1: physiochemical properties of NP
- Biodistribution - target or toxicity?
- FDA approved and under phase
- Current nanotechnology
- Side effects by low dose anticancer drug reduce
- Nanoparticle bio-distribution
- Bio-distribution (graphene)
- Bio-distribution (gold)
- Bio-distribution (iron oxide NP)
- Bio-distribution (carbon dot)
- Consideration
- Minimize RES accumulation
- Physico-therapy (1)
- Physico-therapy (2)
- Aspect ratio is important (1)
- Aspect ratio is important (2)
- Summarized table (1)
- Summarized table (2)
- Part 2: mesenchymal stem cell - nanodrug delivery
- Mesenchymal stem cells (MSCs)
- Iron oxide uptake MSCs
- hMSC-CD90-mwCNT (DOX)
- RGD peptide
- In vivo anti-tumor efficacy of RGD-/PPCD
- MSC cell - Silica NP-CD90+
- Tumor tropism by MSCs
- Summarized table (3)
- Part 3: transportation to cancer organelles
- Endocytic Intracellular Pathways
- Intra-cellular delivery of nanoparticles
- PEG weakness: cytosol release
- Nuclear targeting
- Mito-targeting: electrostatic attraction
- Golgi & ER targeting
- Summarized table: part 3
- Conclusions
- Acknowledgements
Topics Covered
- Rationale: low target efficacy drugs
- Physiochemical properties of nanoparticles
- Mesenchymal stem cell-nanodrug delivery
- Transportation to cancer organelles
Talk Citation
Khang, D. (2015, May 18). Increasing tumor targeting efficacy by nanomedicine [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/OXGE7325.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dongwoo Khang has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Nanomedicine
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name Dongwoo Khang,
professor at the Department
of Molecular Medicine in Gachon
University, located in South Korea.
In this slide, I will
be very happy to share
recent technology to enhance tumor
target by using nanotechnology.
0:15
In this slide, I'll talk
about three chapters
to improve tumor target accuracy.
First, is physiochemical factors
regulating biodistribution,
and second is mesenchymal stem
cell assist in nanodrug delivery.
And last, transportation
to the cancer organelles
will be discussed.
0:34
At the very famous presentation
by Dr. Richard Feynman at APS
meeting about 60 years
ago, nanotechnology of
applied physics and
electronics. So unfortunately
although the medicine is the most
critical issues in human beings.
The nanomedicine was
recently introduced.
This is why, in
biochemical pharmaceutics,
it still follows
traditional approach
or making drugs, and
too much excessive drug
with core side effect.
1:06
This slide is rationale
for discussing
low target efficacy of drug.
For example, when the cancer patient
receives chemotherapy only 2%
of injected drugs will
reach the tumor site.
In other words, 98% of injected
drugs will spread over the rest
the entire body without
targeted drug delivery.
This is the main reason
for inducing side effect.
Currently, antibody targeted
strategy, like EGFR,
records about two times higher
than the combinational drugs.
So this antibody approach, does
not enough to upgrade the quality
of chemotherapy patient.